Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11297183 | 0.93 | MAPT (0.61) | SCN9AMAPT | |
| SCHEMBL3711274 | 0.89 | MCL1 (0.55) | SCN9AMAPT | |
| SCHEMBL13168539 | 0.86 | SCN9A (0.65) | SCN9A | |
| SCHEMBL365163 | 0.85 | SCN9A (0.67) | SCN9A | |
| SCHEMBL25002929 | 0.84 | ADORA3 (0.52) | SCN9AMAPT | |
| SCHEMBL3139184 | 0.83 | SCN9A (0.72) | SCN9A | |
| SCHEMBL4591255 | 0.82 | SCN10A (0.65) | SCN9AMAPT | |
| SCHEMBL3134572 | 0.82 | PLA2G2A (0.57) | SCN9A | |
| SCHEMBL10252369 | 0.81 | SCN9A (0.84) | SCN9A | |
| SCHEMBL364424 | 0.81 | SCN9A (0.59) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765029-B2 | Pyridine compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20150344465-A1 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-12-03 | — | — | US | disclosed |
| US-9120752-B2 | Pyridine compounds as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20130345211-A1 | Pyridine Compounds as Sodium Channel Blockers | PURDUE PHARMA L.P. (US) | 2013-12-26 | — | — | US | disclosed |
| EP-2593434-A1 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | Purdue Pharma LP (US) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007836-A1 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA .LP. (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345211-A1 | Pyridine Compounds as Sodium Channel Blockers | SCN1B, CACNA1A, TRPV1 | SCN9A 98/4885MAPT 2359/4885 |
| US-20150344465-A1 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | SCN1B, CACNA1A, SCN1A | SCN9A 96/4885MAPT 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.